Related Experiment Videos

The treatment of infantile spasms by child neurologists

G B Bobele1, J B Bodensteiner

  • 1Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City.

Insights

Corticotropin (ACTH) is the preferred first-line treatment for infantile spasms, with consistent management observed among pediatric neurologists. This uniformity aids in designing future clinical trials for novel infantile spasms therapies.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Clinical Therapeutics

Background:

  • Infantile spasms (IS) is a severe epilepsy syndrome requiring effective treatment.
  • Limited data exists on the most utilized and clinically relevant IS treatment regimens.
  • Understanding current practices is crucial for designing clinical trials of new IS therapies.

Purpose of the Study:

  • To identify the most commonly used treatment methods for infantile spasms.
  • To establish the practical importance of current treatment strategies in clinical trial design.

Main Methods:

  • A 1991 survey was distributed to Child Neurology Society members regarding IS treatment.
  • Telephone follow-up was conducted on a sample of non-respondents.
  • Response rate was 58.3%.

Main Results:

  • Corticotropin (ACTH) is the first-choice treatment for 88% of respondents.
  • Common ACTH dosage: 40 IU/day for 1-2 months.
  • Valproic acid and oral corticosteroids are alternative treatments.
  • Reported side effects include cushingism, behavioral changes, hypertension, and infections.
  • Treatment patterns were consistent across various respondent demographics and practice types.

Conclusions:

  • A significant uniformity exists in the management of infantile spasms among child neurologists.
  • This consensus supports the use of ACTH as a benchmark in clinical trials for new IS treatments.
  • Current treatment practices provide a foundation for future research into infantile spasms therapies.

Related Concept Videos